Key statistics
On Tuesday, Immunovia AB (publ) (IMMNOV TO 2:STO) closed at 0.0778, -22.20% below its post-IPO high of 0.10, set on Sep 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0946 |
---|---|
High | 0.0984 |
Low | 0.0654 |
Bid | 0.0684 |
Offer | 0.0778 |
Previous close | 0.0934 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Oct 08 2024 17:00 BST.
More ▼
Press releases
- Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
- Immunovia completes analytical validation of its next-generation pancreatic cancer test
- Change in number of shares and votes in Immunovia AB (publ)
- Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
- Immunovia Publishes Interim Report for January-June 2024
- Immunovia's next-generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health
- Immunovia files US patent application to protect its next-generation test
- Immunovia completes development of its pancreatic cancer detection test after substantially increasing test accuracy
- Invitation to Immunovia's Q2 presentation
- Immunovia presents data from discovery study at 2024 PancreasFest medical conference
More ▼